Pentavalent vaccine and adverse events following immunization-untangling the misinterpretations.
In April 2008, the National Technical Group on Immunization (NTAGI) Sub-committee on H. influenza type b (Hib) vaccine recommended that Hib containing pentavalent vaccine should be introduced in the country. Subsequently liquid pentavalent vaccine (LPV) was launched in the Kerala and Tamil Nadu on a pilot basis in December 2011. The introduction of LPV in these two states was followed by reported deaths in infants who had received LPV. An exhaustive summary of media reports and previous literature has since been made available at various fora which have been supplemented with estimations of the damage the LPV may cause. It has thus been concluded that the LPV is bound to cause more number of infant deaths than it will save from Hib meningitis and pneumonia. The current paper aims to clear some of the misinterpretations and miscalculations so that lives of 72,000 infants can be saved.
Ministry of Health and Family Welfare, Government of India, New Delhi, India, drakashmalik28@gmail.com.
Akash
A
Malik
D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects*; D018073:Haemophilus Vaccines / Q000009:adverse effects*; D017325:Hepatitis B Vaccines / Q000009:adverse effects*; D006801:Humans; D007114:Immunization / Q000009:adverse effects*; D007194:India; D007223:Infant; D008583:Meningitis, Haemophilus / Q000517:prevention & control; D011014:Pneumonia / Q000517:prevention & control; D017778:Vaccines, Combined / Q000009:adverse effects*
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D017325:Hepatitis B Vaccines; D017778:Vaccines, Combined; C080881:diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine